Read More

AbbVie Earlier Announced European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn’s Disease

AbbVie (NYSE: ABBV) announced the European Commission (EC) approved SKYRIZI® (risankizumab, 600 mg intravenous [IV] induction and 360 mg subcutaneous [SC] maintenance therapy) as the first specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease who have had in

ABBV